Emerging retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the medical community. Early clinical research have shown impressive losses in physical size and advancements in physiological markers for individuals with excess weight . Experts believe this ground-breaking appro